Kalaris Therapeutics, Inc. (KLRS)
| Market Cap | 129.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.47M |
| Shares Out | 18.70M |
| EPS (ttm) | -3.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,652 |
| Open | 6.93 |
| Previous Close | 6.68 |
| Day's Range | 6.54 - 7.14 |
| 52-Week Range | 2.14 - 12.90 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 21.50 (+211.59%) |
| Earnings Date | Nov 12, 2025 |
About KLRS
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for KLRS stock is "Strong Buy." The 12-month stock price target is $21.5, which is an increase of 211.59% from the latest price.
News
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose se...
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Highly experienced biopharma financial officer joins leadership team CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in trea...
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercializatio...
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to ...
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neova...
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercializatio...
Kalaris to Participate at Stifel Ophthalmology Forum
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization...
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovasc...
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving i...
Kalaris Announces Closing of Merger with AlloVir
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis...